ABSTRACT
The aim of this trial is to evaluate the efficacy outcomes of iEPO verses iNO in patients diagnosed with ARDS secondary to COVID-19. Patients admitted to the ICU from 3-1-20 through 2-28-21 undergoing treatment for ARDS due to COVID-19 with iEPO and/or iNO were included. B Introduction: b According to the Society of Critical Care Medicine guidelines for the treatment of acute respiratory distress syndrome (ARDS) due to COVID-19 for rescue or adjunctive therapy, a trial of inhaled nitric oxide (iNO) or epoprostenol (iEPO) can be considered in addition to prone ventilation, neuromuscular blocking agent infusions (NMBA), and extracorporeal membrane oxygenation (ECMO). [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
The American Thoracic Society Core Curriculum updates clinicians annually in adult and pediatric pulmonary disease, medical critical care, and sleep medicine in a 3- to 4-year recurring cycle of topics. The topics of the 2020 Pulmonary Core Curriculum include pulmonary vascular disease (submassive pulmonary embolism, chronic thromboembolic pulmonary hypertension, and pulmonary hypertension) and pulmonary infections (community-acquired pneumonia, pulmonary nontuberculous mycobacteria, opportunistic infections in immunocompromised hosts, and coronavirus disease [COVID-19]).